Pharmalicensing.com: Industry news http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us Pharmalicensing.com: Industry news http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 Eurand In-licenses Corticosteroid GI Product From Chiesi Farmaceutici SpA PHILADELPHIA, April 15, 2008 -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products... http://pharmalicensing.com/redirs/news_rss//public/news/view/415106/ http://pharmalicensing.com/redirs/news_rss//public/news/view/415106/ POSITIVE RESULTS FROM PHASE I CLINICAL TRIAL OF SMT D002 FOR THE TREATMENT OF SEBORRHOEA, A PRIMARY CAUSE OF ACNE Oxford, UK, 15 April 2008 - Summit Corporation plc (AIM: SUMM), a leading UK biotechnology company, today announces a positive outcome from its repeat-dose Phase I clinical trial of SMT D002, its... http://pharmalicensing.com/redirs/news_rss//public/news/view/414807/ http://pharmalicensing.com/redirs/news_rss//public/news/view/414807/ Pfizer and AVANT Enter into Licensing and Development Agreement for Novel Therapeutic Vaccine Candidate for Brain Cancer NEW YORK & NEEDHAM, Mass.--April 16, 2008--Pfizer, Inc (NYSE: PFE) and AVANT Immunotherapeutics (Nasdaq: AVAN), acting through its wholly-owned subsidiary Celldex Therapeutics, Inc. today announced... http://pharmalicensing.com/redirs/news_rss//public/news/view/415186/ http://pharmalicensing.com/redirs/news_rss//public/news/view/415186/ Meda and Orexo in a potential billion SEK deal April 14, 2008 -- Meda has acquired exclusive world-wide commercialisation rights from Orexo of two patented drugs in late development phase; Sublinox and OX-NLA. http://pharmalicensing.com/redirs/news_rss//public/news/view/414533/ http://pharmalicensing.com/redirs/news_rss//public/news/view/414533/ Roche fully acquires privately-owned biotech company Piramed Basel, 15 April 2008 - Roche announced today that it will acquire Piramed Limited, a privately-owned UK company focusing on therapeutics targeting PI3-kinase (PI3-K). The PI3-K pathway is known to... http://pharmalicensing.com/redirs/news_rss//public/news/view/414893/ http://pharmalicensing.com/redirs/news_rss//public/news/view/414893/